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The transcription factor STAT1 plays a role in promoting apoptotic cell death, whereas the related STAT3
transcription factor protects cardiac myocytes from ischemia/reperfusion (I/R) injury or oxidative stress.
Cytokines belonging to the IL-6 family activate the JAK-STAT3 pathway, but also activate other cytopro-
tective pathways such as the MAPK-ERK or the PI3-AKT pathway. It is therefore unclear whether STAT3 is
the only cytoprotective mediator against oxidative stress-induced cell death. Overexpression of STAT3 in
primary neonatal rat ventricular myocytes (NRVM) protects against I/R-induced cell death. Moreover, a
dominant negative STAT3 adenovirus (Ad ST3-DN) enhanced apoptotic cell death (81.2 ± 6.9%) compared
to control infected NRVM (46.0 ± 3.1%) following I/R. Depletion of STAT3 sensitized cells to apoptotic cell
death following oxidative stress. These results provide direct evidence for the role of STAT3 as a cytopro-
tective transcription factor in cells exposed to oxidative stress.
 2009 Elsevier Inc.Open access under CC BY-NC-ND license.Introduction
Apoptosis has become increasingly recognized as one mecha-
nism of cell death during ischemia/reperfusion (I/R) injury in cul-
tured cardiac myocytes and in the isolated intact heart [1–3].
While research into the underlying molecular mechanisms of I/R
remains challenging there is great potential to uncover candidate
targets for novel therapeutic intervention through elucidation of
the precise signalling cascades that control cell fate following car-
diac damage. One of the pathways which is instrumental in deter-
mining cell fate following the oxidative stress which occurs during
I/R is the JAK-signal transducers and activators of transcription
(STAT) factor pathway [4].
STAT activation is initiated following ligand binding to the
extracellular domain of JAK receptors and autophosphorylation of
the JAK cytoplasmic domain, creating a docking site for the SH2 do-
main of STATs [4]. This association causes JAKs to phosphorylate
STATs at distinct tyrosine residues, allowing the bound STATs to
be released from the receptor and undergo homo- or heterodimer-
sation [4]. Phosphorylated STATs are then translocated to the nu-
cleus where they bind speciﬁc sequences in the promoters of
target genes leading to transcriptional regulation. Recent studies
have shown that STATs can modulate the apoptotic programme
in a variety of cell types [5]. For example, STAT1 deﬁcient cells
are resistant to tumour necrosis factor a-induced apoptotic cellhanou).
-NC-ND license.death [6]. STAT1 also has tumour suppressor properties and is re-
quired to modulate cell cycle checkpoint response following DNA
damage [7]. STAT1 can also function as a co-activator and modu-
late the transcriptional activity of p53 and p73 [8,9]. We have pre-
viously reported that overexpression of STAT1 enhances apoptotic
cell death in cardiac myocytes exposed to simulated I/R [10,11]. In
contrast to STAT1, the related STAT3 transcription factor has onco-
genic properties and is overexpressed in many cancers [12,13]. In
vitro studies have described cytoprotective actions of STAT3 activ-
ity following cytokine stimulation in cardiac cells exposed to I/R
[14]. Additional in vivo studies have conﬁrmed that hearts from
transgenic mice expressing a constitutively active STAT3 are pro-
tected from I/R injury [15]. STAT3 is also required for ischaemic
preconditioning in the brain [16], and liver [17], as well as in the
heart [18].
Many of the in vitro studies of STAT3 relied on cytokines that
activated the JAK-STAT3 pathway. However, these cytokines are
also known to activate other cytoprotective pathways such as the
MAPK-ERK and the PI3-AKT pathways. In the present study we
examined whether genetically depleting STAT3 in the absence of
cytokine stimulation compromises cytoprotection.
Materials and methods
All reagents were obtained from Sigma–Aldrich unless other-
wise stated. STAT3 deﬁcient mouse embryonic ﬁbroblasts were a
kind gift from Prof. Valeria Poli, University of Turin, Italy and were
maintained in Dulbecco’s modiﬁed Eagle’s medium (DMEM) sup-
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p21 reporter construct was a kind gift from Dr. W. El-Deiry, Univer-
sity of Pennsylvania, Pennsylvania, USA and the Ly6E and STAT3
constructs were kind gifts from James Darnell, Rockefeller Univer-
sity, New York.
Neonatal rat ventricular cardiac myocyte culture. Neonatal rat
ventricular cardiac myocytes (NRVM) were isolated from the
hearts of 1- to 3-day-old Sprague Dawley rats as previously de-
scribed [10].
Determination of cardiac myocyte viability and assesment of cell
death by ﬂow cytometry.Measurement of cell death by Trypan Blue
was carried out as previously described [10]. Annexin V and 7AAD
ﬂuorescence was measured using a Becton Dickinson ﬂow cytom-
eter. Cell death is given as the combined percentage of cells posi-
tive for Annexin V (apoptotic cells) and 7AAD (necrotic cells).
Terminal dUTP nick end labelling (TUNEL). Labelling of 30-hydro-
xyl ends of DNA fragments was performed using terminal deoxy-
nucleotidyl transferase (TdT) and rhodamine conjugated
nucleotides (Roche, Hertfordshire, UK). Cells were grown on 1%
gelatin coated coverslips and transfected for 48 h with 0.25 lg
pcDNA3 or STAT3 per well and co-transfected with 0.5 lg GFP. Fol-
lowing I/R injury, cells were washed in PBS and ﬁxed for 10 min in
4% paraformaldehyde. The TUNEL assay was performed as previ-
ously described [10].
Luciferase reporter assays. Cells were seeded in 24 well plates
and transfected with 0.5 lg luciferase reporter construct and
50 ng CMV-renilla per well. After 24 h, cells were lysed in passive
lysis buffer (Promega) and luciferase activity was measured using
the dual luciferase reporter system according to the manufac-
turer’s instructions. Relative luciferase activity was calculated as
luciferase activity/renilla activity and normalised to controls.
Adenoviral infections. The dominant negative STAT3 and GFP
adenoviruses were kind gifts from Prof. Brian Foxwell, Imperial
College London, UK and the STAT3C adenovirus was a kind gift
from Prof. Michitaka Ozaki, Okayama University, Japan. Recombi-
nant viruses were propagated using human embryonic kidney
293 cells and puriﬁed through a cesium chloride gradient and
PD-10 column (GE Healthcare). Viral titre was determined by pla-
que assay in 293 cells. Viral transduction was carried out by incu-
bating cells at the indicated multiplicity of infection (MOI) in
serum free medium, after 2 h cells were washed and fresh media
added.
Quantitative real-time PCR (qPCR). One micro gram of RNA ex-
tracted from cardiac myocytes and cDNA was prepared using
Superscript II (Invitrogen, Paisley, UK) and random hexamers (Pro-
mega, UK). qPCR was carried out using Platinum SYBR Green (Invit-
rogen, Paisley, UK) on the DNA Engine Opticon system (MJ
Research, Waltham, MA). HPRT, Actin and GAPDH were used to-
gether as normalising genes and for each experiment both target
and normalising gene PCR efﬁciency was ﬁrstly determined to en-
sure normalizing genes were acceptable. To test primer efﬁciency,
qPCR was carried out on a 2-fold dilution series from a pooled set
of cDNA and the threshold Ct value was plotted against the log
cDNA dilution. Efﬁciency was then calculated using the equation
m = (1/log E), where m is the slope of the line and E is the efﬁ-
ciency and primer pairs were used only if the PCR efﬁciency of
the normalising and control genes were found to be within 10%
of each other. Expression changes were claculated using the 2DDCt
method and expressed as fold change over control [20]. Speciﬁc
primers were designed with the aid of CloneWorks and the Ensem-
bl database and are shown below.Primer Primer sequenceSocs3 forward 5’-TGGTCACCCACAGCAAGTTT-3’
Socs3 reverse 5’-ACCAGCTTGAGTACACAGTC-3’c-Fos forward 5’-GCCTTTCCTACTACCATTCC-3’
c-Fos reverse 5’-CCGTTTCTCTTCCTCTTCAG-3’Hprt forward 5’-CTCATGGACTGATTATGGACAGGAC-3’
Hprt reverse 5’-GCAGGTCAGCAAAGAACTTATAGCC-3’Actin forward 5’-AGATGACCCAGATCATGTTTGAG-3’
Actin reverse 5’-AGGTCCAGACGCAGGATG-3’Gapdh forward 5’-GTGTGAACGGATTTGGCCG-3’
Gapdh reverse 5’-CCAGTAGACTCCACGACATA-3’Western blot. Antibodies against the phosphorylated pSTAT3Y705 and
pSTAT3S727 were purchased from Cell Signaling Technology, MA,
USA, pSTAT1Y701 was from Zymed, CA, USA, pSTAT1S727 was from
Upstate, Cambridge, UK, caspase-9 was from Santa Cruz Biotechnol-
ogy, CA, USA and GAPDH was from Chemicon, CA, USA. Horseradish
peroxidase-conjugated secondary antibodies were from Dako
(Glostrup, Denmark).
Statistical analysis. Data are expressed as means ± SEM, all
experiments were repeated in triplicate. Statistical analysis was
carried out using a Student’s t-test, one-way ANOVA with Dunnet’s
post or two-way ANOVA with Bonferroni post test, p-values of less
than 0.05 were considered signiﬁcant.Results
Overexpression of wild type STAT3 protects against cell death in
cardiac myocytes exposed to I/R whereas, a STAT3Y705F mutant
enhances I/R-induced cell death
To determine whether STAT3 has a direct role in modulating the
levels of cell death, we carried out transient transfection experi-
ments in primary neonatal rat ventricular myocytes (NRVM) ex-
posed to I/R injury. As shown in Fig. 1A transient expression of
wild type STAT3 signiﬁcantly reduced the levels of apoptotic cell
death from 50 ± 5% to 31 ± 7% in NRVM exposed to I/R. This sug-
gests that STAT3 may indeed function as a cytoprotective factor
in cells subjected to oxidative stress. In order to show and conﬁrm
that transfection and overexpression of STAT3 allows it to mediate
its transcriptional activity we also carried out reporter luciferase
assays using two well characterised STAT3 target promoters, p21
and Ly6E [21,22]. In both cases transient expression of STAT3 in-
duced a 3-fold increase of p21 and Ly6E promoter activity in NRVM
(Fig. 1B), thus conﬁrming that STAT3 is transcriptionally active
when overexpressed in NRVM.
To further clarify the role of STAT3 in NRVM following I/R in-
jury, we utilized a mutant STAT3 adenovirus in which the tyrosine
(Y705) was mutated to a phenylalanine (F705). This mutant has
been shown to act as a dominant negative (ST3-DN) [23]. Impor-
tantly, this approach using an adenoviral STAT3Y705F allows us to
transduce > 90% of NRVM and as indicated in Fig. 1C, ST3-DN en-
hanced signiﬁcantly the effects of I/R-induced death to
81.2 ± 6.9% compared with control (GFP) infected cells
46.0 ± 3.1%. This data provides further evidence that a fully trans-
criptionally active STAT3 that requiring the 705 tyrosine phosphor-
ylation site is necessary for its cytoprotective properties.Deletion of STAT3 sensitizes cells to cell death
While overexpression using a variety of methods is useful to
examine the effects of factors on cell fate, it may lead to spurious


































































Fig. 1. STAT3 protects cardiac myocytes from I/R injury. (A) Cardiac myocytes were transfected with 0.5 lg GFP and 0.25 lg STAT3-pcDNA3 or pcDNA3 empty vector for 48 h
and subjected to I/R injury for the indicated times. Cell death was measured using TUNEL, a minimum of 200 GFP positive cells were counted per experiment. Experiments
were repeated in triplicate, and statistical analysis was carried out using a 2-way ANOVA with a Bonferroni post test, *p < 0.05. (B) STAT3 is transcriptionally active in neonatal
rat ventricular myocytes; 0.5 lg of the p21 or Ly6E promoter construct and 50 ng CMV-renilla were transfected into cardiac myocytes with 0.5 lg STAT3 or pcDNA3.
Luciferase activity was measured after 48 h and expressed as relative luciferase units (RLU) normalised to 1. *p < 0.05, ***p < 0.001, Student’s t-test, n = 3, experiment repeated
in triplicate. (C) Dominant negative STAT3 increases I/R-induced cell death in cardiac myocytes. Cardiac myocytes were transduced for 48 h with control Ad GFP or Ad STAT3-
DN at MOI = 100. Cells were then subjected to 4 h ischaemia and 16 h reperfusion and cell death was measured using annexin V and 7AAD staining, *p < 0.05, **p < 0.01, one
way ANOVA with Bonferroni post test, n = 3 per group, average of two experiments.
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fore, utilized STAT3 deﬁcient mouse embryonic ﬁbroblasts (MEF)
to further examine the role of STAT3 in MEF cells exposed to I/R in-
jury. Interestingly, as indicated in Fig. 2A, STAT3 deﬁcient MEF cells
were very sensitive to I/R injury compared to wild type MEF cells
with very few STAT3 deﬁcient MEFs (ST3/) remaining attached
to the culture dishes following 4 h of simulated ischaemia and 16 h
of reperfusion (Fig. 2A lower panel). We therefore, reduced the
simulated ischaemic period from 4 h to 2 h and the simulated
reperfusion period from 16 h to 1 h and once again as shown
in Fig. 2B, there was signiﬁcantly enhanced cell death in the
ST3/ MEF compared to wild type MEF ST3+/+ cells. Since MEF
cells are not usually exposed physiologically to I/R we instead sub-
jected MEF cells to H2O2 as a model of oxidative stress. Once again,
ST3/ cells were signiﬁcantly more sensitive to cell death than
ST3+/+ MEF cells in a dose and time dependent manner (Fig. 2C
and D). These data are further evidence that STAT3 deﬁciency ren-
ders cells more susceptible to oxidative stress.
Activated STAT3 is induced following I/R
The above data demonstrates that exogenous levels of STAT3
are cytoprotective in cardiac myocytes exposed to I/R injury. How-
ever, it is unclear whether endogenous STAT3, phospho-
pSTAT3Y705 or pSTAT3S727 is activated in NRVM during I/R. As
shown in Fig. 3A, pSTAT3Y705 levels increased following 4 h of
ischaemia peaked at 1 h of reperfusion. The levels of pSTAT3Y705 re-
mained elevated even after 20 h of reperfusion compared to con-
trol resting cells. The levels of pSTAT3S727 also increased
following 4 h of ischaemia and again peaked at the 1 h reperfusion
time point, but unlike pSTAT3Y705, pSTAT3S727 returned to controllevels thereafter. As previously reported in the isolated intact heart
[10], STAT1 phosphorylation of pSTAT1Y701 was also enhanced dur-
ing ischaemia and remained elevated 20 h after reperfusion in
NRVM (Fig. 3B) and this was also associated with increased apop-
totic activity as assessed by the processing and cleavage of procas-
pase-9. In contrast, pSTAT1S727 was increased during ischaemia,
but decreased over time following reperfusion (Fig. 3B).
To conﬁrm that endogenous STAT3 activity was enhanced fol-
lowing I/R, we carried out our Ly6E STAT3 responsive reporter as-
say and showed that there was a signiﬁcant increase (40-fold) in
Ly6E promoter activity in NRVM cells exposed to I/R (Fig. 3C). Fur-
thermore we also demonstrate that two well known STAT3 respon-
sive genes SOCS3 [25] and c-Fos [26] were also upregulated in
NRVM cells exposed to I/R as assessed by qPCR (Fig. 3D). As a po-
sitive control we also transduced NRVM with a constitutively ac-
tive STAT3 adenovirus (Ad-STAT3C) [27] and showed that
enhanced levels of STAT3 activity was also associated with upreg-
ulation of SOCS3 and c-Fos mRNAs (Fig. 3E). Taken together, these
data strongly suggests that endogenous STAT3 does indeed become
activated and induces a transcriptional programme that may mod-
ulate the levels of I/R-cell death in cardiac cells.Discussion
Myocardial infarction or I/R injury results from occlusion of
blood ﬂow in the left ventricle via the coronary arteries, leading
to cardiac damage, cell death and eventually loss of cardiac output.
The molecular mechanism that mediates myocardial damage fol-
lowing I/R are not fully understood. STAT transcription factors have













































































Fig. 2. STAT3/ MEFs are highly sensitive to H/R damage. (A) STAT3+/+ and STAT3/ MEFs were subjected to 4 h ischaemia and 16 h reperfusion and visualised under
light microscopy. (B) MEFs were subjected to 2 h ischaemia followed by 1 h reperfusion and cell death was quantiﬁed by annexin V/7AAD staining (left) and trypan blue
uptake (right) *p < 0.05, Student’s t-test, n = 3 per group, average of three experiments (C) STAT3+/+ and STAT3/ MEFs were treated with indicated concentrations of H2O2
for 24 h and cell death was assessed by annexin V/7AAD staining. (D) STAT3+/+ and STAT3/ MEFs were treated with 0.5 mM H2O2 for the indicated times and cell death
was measured by trypan blue uptake. For C and D, statistical analysis was carried out using a 2-way ANOVAwith Bonferroni post test, *p < 0.05, **p < 0.01, ***p < 0.001, n = 3 per
group, experiment repeated in triplicate.
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onstrates that STAT3 plays a cytoprotective role in cardiac cells ex-
posed to I/R injury and oxidative stress and that depleting STAT3 in
the absence of cytokine stimulation compromises cytoprotection.
Recently we showed that the levels of phosphorylated STAT1
and STAT3 are signiﬁcantly modulated in the infarcted area in
the in vivo rat myocardium exposed to I/R injury [28]. Thus, the
free radical scavenger tempol reduced STAT1 and STAT3 phosphor-
ylation and reduced the infarct size following I/R [28], suggesting
that activation of STAT1 and STAT3 within the infarct area may
contribute to cardiac remodelling. Also free radical production fol-
lowing I/R injury may be a trigger for distinct kinases that are
responsible for STAT1 or SATAT3 phosphorylation.
STAT1 overexpression has been shown to induce apoptosis in
cardiac myocytes after I/R injury in vitro, [11]. Our previous
in vivo studies also showed both STAT1 and STAT3 phosphorylation
is enhanced but with different time kinetics [28]. Although it was
observed that there was less overall activated STAT3 in the in-farcted heart, it may still counteract the effects of activated STAT1
and reduce the degree of damage. This was further highlighted fol-
lowing IFN-c treatment, a potent activator of STAT1, which exacer-
bated cardiac damage as evidenced by increased infarct size [28].
Moreover, IFN-c-induced STAT1 activation during reperfusion
and signiﬁcantly reduced the cardioprotective effect of tempol,
indicating that this antioxidant’s anti-apoptotic effect is likely to
be mediated partly through reduction in activated STAT1 [28].
Since we previously showed that the cardioprotective affects of
epigallocatechin-3-gallate (EGCG), a natural antioxidant found in
green tea, were partly mediated by inhibition of STAT1 activity
[29], this highlights the role of STAT1 as a general molecular target
for antioxidants in the ischemic myocardium.
Although total STAT3 deletion is embryonic lethal, these mice
had developmental heart defects also suggesting an important role
for STAT3 in cardiac development [24]. Generation of cardiac-spe-
ciﬁc STAT3 knock outs further highlighted the important role of






















































































Fig. 3. Activation of STAT3 following I/R injury. NRVMs were subjected to 4 h ischaemia or ischaemia plus the indicated times of reperfusion and lysates were subjected to
Western blotting using antibodies for (A) tyrosine and serine phosphorylated STAT3 or (B) tyrosine and serine phosphorylated STAT1 and caspase-9. GAPDH was used as a
loading control. (C) STAT3 dependent luciferase reporter activity is enhanced by I/R injury. 1 lg of Ly6E luciferase reporter and 0.1 lg CMV-renilla were transfected into
NRVMs in 6-well plates for 24 h. Cells were then subjected to 4 h ischaemia and 24 h reperfusion (I/R) and luciferase activity was measured ***p < 0.001, n = 3, experiment
repeated in duplicate. (D) STAT3 dependent gene expression is increased by I/R injury. NRVMs were subjected to a time course of I/R injury and the levels of SOCS3 and c-Fos
were measured by qPCR and normalised to control (con) levels. Isc = Ischaemia alone without reperfusion. Statistical analysis was carried out using a one-way ANOVA with
Dunnett’s post test, n = 3 samples, experiments repeated in triplicate, *p < 0.05, **p < 0.01 compared to con. (E) NRMVs were transduced with STAT3C adenovirus at MOI = 100.
After 24 h, the expression of SOCS3 and c-fos and was examined by qPCR. **p < 0.01, Student’s t-test, n = 3 per group, repeated in duplicate.
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[25,26]. Furthermore these mice were more susceptible to I/R-in-
duced cardiac damage and had larger infarct sizes and increased
myocyte apoptotic cell death [30,31].
Granulocyte-colony stimulating factor (G-CSF) has been re-
ported to confer cardioprotection, reduced infarct size and inhib-
ited apoptotic cell death. These effects of G-CSF were abolished
by in mice expressing an inactive STAT3 in cardiac myocytes, sug-
gesting that the cardioptotective effects are mediated via G-CSF-
JAK-STAT3 pathway [32]. Thus, these data are further evidence that
STAT3 has cytoprotective properties and in particular highlight a
role for STAT3 in cardioprotection.
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